We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current KRYS market cap is 4.84B. The company's latest EPS is USD 3.0951 and P/E is 54.17.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.14M | 45.25M | 70.29M | 83.84M | 91.14M |
| Operating Income | 3.14M | -6.68M | 8.57M | 22.43M | 41.38M |
| Net Income | 8.69M | 932k | 15.57M | 27.18M | 45.48M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 50.7M | 290.52M |
| Operating Income | -33M | -68.28M | -145.2M | -109.73M | 65.7M |
| Net Income | -32.17M | -69.57M | -139.98M | 10.93M | 89.16M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 818.36M | 853.3M | 917.66M | 982.32M | 1.06B |
| Total Liabilities | 39.71M | 54.05M | 78.77M | 96.47M | 109.46M |
| Total Equity | 778.64M | 799.24M | 838.89M | 885.85M | 946.38M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 310.84M | 626.3M | 558.45M | 818.36M | 1.06B |
| Total Liabilities | 18.76M | 32.72M | 36.22M | 39.71M | 109.46M |
| Total Equity | 292.08M | 593.58M | 522.23M | 778.64M | 946.38M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -88.8M | 15.89M | 11.72M | 70.58M | 123.42M |
| Investing | 82.64M | -25.98M | -45.33M | -79.66M | -163.44M |
| Financing | 202.75M | 10.58M | 21.22M | 24.59M | 27.01M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -26.08M | -47.94M | -100.57M | -88.8M | 123.42M |
| Investing | -11.18M | -226.77M | -114.08M | 82.64M | -163.44M |
| Financing | 118.02M | 347.69M | 35.35M | 202.75M | 27.01M |
| Market Cap | 4.84B |
| Price to Earnings Ratio | 54.17 |
| Price to Sales Ratio | 16.62 |
| Price to Cash Ratio | 14 |
| Price to Book Ratio | 5.1 |
| Dividend Yield | - |
| Shares Outstanding | 28.81M |
| Average Volume (1 week) | 260.71k |
| Average Volume (1 Month) | 341.26k |
| 52 Week Change | 7.86% |
| 52 Week High | 219.34 |
| 52 Week Low | 141.72 |
| Spread (Intraday) | 102.28 (37.83%) |
| Company Name | Krystal Biotech Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.krystalbio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
